XML 69 R17.htm IDEA: XBRL DOCUMENT v3.21.2
SEGMENTS
 6 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
SEGMENTS

11. SEGMENTS

 

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed. We record discrete financial information for ESI and our chief operating decision maker reviews ESI’s operating results in order to make decisions about resources to be allocated to the ESI segment and to assess its performance.

 

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

 

The following tables set forth certain information regarding our segments:

        
   Six Months Ended September 30, 
   2021   2020 
Revenues:        
Aethlon  $263,932   $– 
ESI   –    – 
Total Revenues  $263,932   $– 
           
Operating Losses:          
Aethlon  $(4,097,441)  $(3,174,095)
ESI   (9,801)   (8,440)
Total Operating Loss  $(4,107,242)  $(3,182,535)
           
Net Losses:          
Aethlon  $(4,097,441)  $(3,174,095)
ESI   (9,801)   (8,440)
Net Loss Before Non-Controlling Interests  $(4,107,242)  $(3,182,535)
           
Cash:          
Aethlon  $23,224,728   $14,473,035 
ESI   197    197 
Total Cash  $23,224,925   $14,473,232 
           
Total Assets:          
Aethlon  $23,873,988   $15,056,193 
ESI   197    197 
Total Assets  $23,874,185   $15,056,390 
           
Capital Expenditures:          
Aethlon  $78,861   $23,137 
ESI   –    – 
Capital Expenditures  $78,861   $23,137 
           
Depreciation and Amortization:          
Aethlon  $80,690   $18,041 
ESI   –    – 
Total Depreciation and Amortization  $80,690   $18,041